The most important thing in real estate is "location, location, location" -- but in the pharmaceutical industry it's "innovation, innovation, innovation." Drugmaker AstraZeneca (AZN +0.12%) is grappling with the effects of some massive drug patent expirations and is under pressure to innovate quickly. The week, the company's recently appointed CEO changed up both personnel and structure in his management team. In this video, our health-care analysts discuss these changes and how they might jump-start an R&D revolution at the company.
Is the transformation complete, or does this drugmaker still have a lot of work ahead?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo